ISS I: Ovarian Cancer Tumor Board: Leveraging Evolving Data Sets on PARP Inhibitors to Inform Treatment Decision-Making

MTCC: 701

CME Provided by Physicians’ Education Resource, LLC (PER); this symposium is supported by AstraZeneca, Merck, and TESARO, a GSK Company.

Course Director:
Robert L. Coleman, MD, FACOG, FACS, The University of Texas MD Anderson Cancer Center, Houston, TX

Susana M. Campos, MD, MPH, Dana-Farber Cancer Institute, Boston, MA
Don S. Dizon, MD, FACP, Lifespan Cancer Institute – Rhode Island Hospital, Providence, RI
Kathleen Moore, MD, The University of Oklahoma, Oklahoma City, OK

This activity will bring together renowned international experts in ovarian cancer treatment and clinical research in for an in-depth mock tumor board that will assess the clinical impact of recent and emerging trial data for PARP inhibitors in ovarian cancer treatment. A series of case presentations will be presented with clinical trial data tightly integrated to illuminate front-line, later line, maintenance, sequencing, and switching throughout the ovarian cancer treatment paradigm. Adverse events and management will be educationally tied to case presentations. Future directions in the field will also be addressed and considered regarding how recent developments and highly anticipated trials may shape care. Faculty will be present onstage throughout the program. Audience participation will be integrated throughout to encourage interaction with faculty and engagement with the content.